We are Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate CAS:147118-35-2 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Chemical Name: Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate
3-(tert-butyldimethylsilanyloxy)-5-oxo-6-(triphenylphosphanylidene)hexanoic acid methyl ester
(3R)-3-(tert-butyldiMethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate Methyl ester
Molecular Formula: C31H39O4PSi
Molecular Weight: 534.69800
Physical and Chemical Properties:
Density: 1.1 g/cm3
Boiling point: 603.9ºC at 760 mmHg
Melting point: 77.5-78.5ºC
Flash point: 319ºC
Refractive index: 1.553
Appearance: White or light yellow crystalline powder
Loss on drying:≤2.0%
Single impurity: 1.0%max
Specific optical rotation:Between -5.2º to-7.2º
25kg cardboard drum or according to customer specified requirements
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Intermediates of Rosuvastatin CAS:287714-41-4.
Related News: ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses.4- [4-Fluoro-3- (1-piperazinilcarbonil) bencil] -1 (2H) -ftalazinona CAS:763111-47-3 After testing, our quality assurance staff confirms that everything has been performed correctly in accordance with GMP from manufacturing of API to quality testing.1-isocyanato-4-propan-2-yl benzene The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.Bencil 3-oxoazetidina-1-carboxilato CAS:105258-93-3 The company’s short-term plan is to move from a purely chemical intermediate manufacturer to a formula active material supplier, and its long-term goal is to become a solution provider in the selected segment. In the future, this business is expected to become a new growth point for the company’s profit.China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.